A high-stakes battle over the future of weight-loss medication began Thursday as telehealth provider Hims & Hers announced the launch of a low-cost, oral version of semaglutide, prompting an immediate legal threat from pharmaceutical giant Novo Nordisk. Hims & Hers revealed it would sell a compounded version of the weight-loss drug for just $49 for the first month—significantly undercutting the $149 price tag of Novo Nordisk’s branded pill. While Hims & Hers previously offered injectable versions of the drug, this move expands their portfolio to include an oral alternative for patients who wish to avoid needles. The Danish drugmaker, which holds the patent for semaglutide until 2032, responded aggressively. In a statement, Novo Nordisk condemned the product as an "unapproved, inauthentic, and untested knockoff". The company argued that the product represents "illegal mass compounding" rather than legitimate personalized medicine and warned that it poses significant risks to patient safety. Novo specifically noted that its own FDA-approved pill uses proprietary SNAC technology to ensure proper absorption, questioning how the Hims formulation could match its efficacy. Hims & Hers is utilizing a regulatory framework that allows for "compounded" medications—drugs custom-mixed for specific patients—to bypass standard FDA approval processes. Although the FDA declared the shortage of GLP-1 drugs over in 2024, an exception remains for "personalized" prescriptions. Hims argues its pill is personalized for patients needing specific dosage adjustments or those trying to minimize side effects. However, the FDA has previously warned the company regarding "deceptive advertising" that blurs the line between approved drugs and compounded copies. The market reaction was swift. Shares of Novo Nordisk fell roughly 7% to 8% following the announcement, compounding a difficult year for the company, which recently forecast a decline in sales and profits for 2026. Meanwhile, Hims & Hers stock saw initial gains before volatility set in as investors weighed the potential profits against the looming legal fight. 🔖 Sources Novo Nordisk says it will take legal action after Hims & Hers reveals $49 copy of Wegovy pill Hims & Hers launches copy of Wegovy pill, prompting legal threats from drugmaker Novo Nordisk Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding Keywords: Wegovy Copycat Pill Wegovy Copycat Pill

F or decades, the diagnosis and management of Type 2 diabetes have revolved around a single, convenient fluid: blood. However, a massive new international study suggests that relying on blood samples alone may mean missing the vast majority of the biological story. Published this week in Nature Metabolism , the research analyzed genetic data from over 2.5 million individuals worldwide. The findings are stark: the biological roots of diabetes are often invisible in the bloodstream. According to the study, 85% of the genetic effects driving the disease within specific organs—such as the liver, pancreas, and fatty tissue—do not appear in blood-based analyses. “Our analysis shows how incomplete it is to try to explain mechanisms using data from blood alone,” said Dr. Ozvan Bocher of the Institute of Translational Genomics at Helmholtz Munich. The study, led by researchers from Helmholtz Munich and the University of Massachusetts Amherst, utilized a "natural experiment" approach. By examining genetic variants fixed at conception, scientists traced how specific genes influence diabetes risk across seven different disease-relevant tissues. They identified 676 genes with causal evidence linked to diabetes. The results highlight a critical blind spot in modern medicine. A patient’s blood test might appear “normal” while disease-driving processes are actively unfolding in insulin-producing beta cells or skeletal muscle. For example, the study found that only 18% of the genes affecting the pancreas showed a corresponding signal in the blood. Furthermore, the research emphasizes the necessity of diversity in medical data. By including individuals of European, African, American, and East Asian ancestry, the team discovered genetic associations that would have remained invisible if the study had focused solely on one population. These findings explain why some drug targets fail despite promising initial data and why patients with similar blood sugar levels often respond differently to the same treatment. By mapping these tissue-specific mechanisms, scientists hope to develop more effective, personalized treatments that target the source of the disease rather than just its symptoms in the blood. 🔖 Sources Big data make hidden genetic drivers of type 2 diabetes visible Massive global study rewrites what we know about Type 2 diabetes biology Massive Global Study Rewrites the Biology of Type 2 Diabetes Keywords: Type 2 Diabetes Type 2 Diabetes

E li Lilly and Company is significantly broadening its medical portfolio, moving beyond its well-known weight-loss and diabetes treatments to secure a foothold in next-generation genetic medicine and advanced manufacturing. The pharmaceutical giant recently entered a major collaboration with Germany-based Seamless Therapeutics  to develop treatments for hearing loss. This agreement, valued at up to $1.12 billion , provides Lilly with access to a proprietary gene-editing platform. Unlike traditional methods that rely on a cell’s own DNA repair pathways, this technology uses programmable recombinases . These are specially engineered enzymes designed to make large, precise changes to DNA to correct specific mutations linked to hearing loss. Lilly will oversee the program’s journey from early preclinical research through to full commercialization. While drugs like Zepbound and Mounjaro continue to drive massive revenue, Lilly is aggressively diversifying its interests: Autoimmune Disease:  The company has partnered with Repertoire Immune Medicines  to focus on new therapies in this sector. Heart Health:  Last year, Lilly spent $1.3 billion  to acquire Verve Therapeutics, further expanding its reach into gene-editing for cardiovascular conditions. Manufacturing Power:  To support its next generation of injectable therapies, Lilly is committing $3.5 billion  to construct a new manufacturing facility in Pennsylvania. As of early 2026, Eli Lilly’s stock (LLY) has shown remarkable long-term growth, rising over 216% over the last three years . Despite this strength, the company faces "execution and capital allocation questions" as it commits massive sums to these new projects. Analysts note that while the stock trades roughly 20% below its estimated fair value , investors should keep a close watch on the company’s high debt levels and the progress milestones of these new collaborations. These strategic moves will ultimately determine how the company’s earnings mix evolves relative to its current dominance in weight management. 🔖 Sources   Eli Lilly (LLY) Taps Gene-Editing Technology to Target Hearing Loss, Reuters Reports   Eli Lilly Expands Weight Loss And Pipeline Bets As Valuation Draws Focus Keywords: Eli Lilly Gene-Editing Eli Lilly Gene-Editing

F or decades, medical science has treated the most common kidney stones as simple mineral deposits, essentially "sterile" aggregates of chemicals formed by a lack of hydration. However, a groundbreaking study led by researchers at UCLA  has shattered this conventional wisdom, revealing that these stones are actually interwoven with living bacterial colonies  that may actively drive their growth. Urologist Kymora Scotland  and her team discovered that calcium oxalate stones —which account for roughly 80 percent  of all cases—are not just mineral blocks but are filled with organized communities of bacteria known as biofilms . Using advanced imaging, the researchers found that these microbes are not just on the surface but are entombed deep within the stone's internal architecture , forming regular layers between mineral deposits. The discovery explains a long-standing mystery: why kidney stones have such a high recurrence rate, reaching up to 80 percent  in some patients. If viable bacteria remain hidden inside even small stone fragments after surgery, they can act as a "seed" for new stones to grow. Remarkably, the team successfully cultured living microbes from 17 out of 22 analyzed stones , including samples from patients who showed no symptoms of a urinary tract infection. The study identifies a fascinating biological survival mechanism as the culprit. Because urine is high in calcium, bacteria release extracellular DNA  to manage the calcium levels around them. This DNA is highly negatively charged, causing calcium ions to condense around it. These "calcium-dressed" DNA molecules then become nucleation sites , acting as templates where crystals begin to form and eventually encase the bacteria. This shift from a chemical to a biological model of stone formation  could revolutionize how the condition is treated for the 1 in 11 people  it afflicts. Instead of relying solely on hydration and dietary changes, future therapies may target the microbial ecosystems  inside the stones or use medications to disrupt the biofilms that allow them to grow. "This breakthrough challenges the long-held assumption that these stones develop solely through chemical and physical processes," Scotland noted, opening the door to new prevention strategies  that could finally break the cycle of recurrent stones. 🔖 Sources   Surprising Find Inside Kidney Stones Suggests We Were Wrong About How They Form   Most Kidney Stones May Actually Be Bacterial Colonies Keywords: Bacteria in Kidney Stones Bacteria in Kidney Stones

A massive global analysis published in the journal Nature Medicine  has revealed that nearly 40% of new cancer cases  worldwide are potentially avoidable. By examining data from 185 countries  and 36 different types of cancer , researchers estimated that 7.1 million of the 18.7 million  new diagnoses in 2022 were linked to modifiable risk factors. These are factors that can be changed, controlled, or managed to reduce the likelihood of developing the disease. The study identified tobacco smoking  as the primary contributor to the global cancer burden, accounting for approximately 15% of all preventable cases . Following smoking, infections  (such as HPV and hepatitis) were responsible for 10%, while alcohol consumption  accounted for 3%. In the UK, the figures align closely with global trends; roughly 32.6% of new cases  (over 148,000) were deemed preventable, with smoking, excess weight, and ultraviolet (UV) radiation  from the sun and sunbeds topping the list of causes. The impact of these risk factors varies significantly by gender and geography. Globally, 45% of new cancer cases among men  were linked to preventable risks, compared with 30% among women . In women, infections like human papillomavirus (HPV)  are a major driver, particularly in low- and middle-income regions like sub-Saharan Africa, where cervical cancer  is highly prevalent. Conversely, in high-income regions like Europe and North America, smoking is the dominant cause of preventable cancer in both sexes. Experts from the World Health Organization (WHO)  and the International Agency for Research on Cancer (IARC)  emphasize that this data should drive "good news" and hope, rather than stigma. Dr. Andre Ilbawi, WHO team lead for cancer control, noted that investing in prevention delivers wide-ranging health, societal, and economic benefits . The research underscores that a "one-size-fits-all"  prevention strategy is insufficient. Instead, experts call for policy and structural solutions  tailored to the specific cancer profiles of different regions, focusing on risk reduction  and respecting the dignity of those living with the disease. By targeting these modifiable habits, nations have a powerful opportunity to slash the future global cancer burden. 🔖 Sources More than one-third of cancer cases are preventable, massive study finds Analysis reveals top preventable cancer causes in UK World Cancer Day: These are the top most preventable causes of cancer, new study finds Keywords: Preventable Cancer Cases Preventable Cancer Cases

N ovo Nordisk reported on February 2, 2026, that its next-generation experimental shot, CagriSema, successfully met primary objectives  in a Phase 3 clinical trial. The study, known as REIMAGINE 2, involved over 2,700 adults with Type 2 diabetes who were also classified as overweight or obese. CagriSema is a fixed-dose combination of semaglutide  (the active ingredient in Wegovy and Ozempic) and cagrilintide , an analog that mimics the pancreatic hormone amylin. In the 68-week trial, participants receiving the 2.4-mg dose of CagriSema achieved a 1.91 percentage point reduction  in HbA1c (a marker of long-term blood sugar), compared to a 1.76 point reduction for those on semaglutide alone. The drug also demonstrated superior weight-loss capabilities. Participants on CagriSema lost 14.2% of their body weight , while those treated with Wegovy lost 10.2%. Despite these gains, the drug fell short of Novo’s internal benchmark of 25% weight loss , a target analysts described as "lofty". The data strengthens Novo Nordisk’s position in its rivalry with Eli Lilly, whose drug Zepbound  has become a global leader in the obesity market. While CagriSema’s current results appear numerically lower than some of Zepbound’s previous data, a high-stakes head-to-head trial  comparing the two is expected to release results by the end of March 2026. Novo Nordisk filed for FDA approval of CagriSema as a weight-loss treatment in December 2025. Martin Holst Lange, Novo’s chief scientific officer, stated that the drug could become the first amylin-based combination therapy  on the market, offering a promising option for individuals managing both diabetes and weight loss. Side effects reported were typical of GLP-1 therapies, primarily involving gastrointestinal issues like nausea. 🔖 Sources   Novo Nordisk's next-gen obesity drug outperforms Wegovy in late-stage diabetes trial   Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III Novo combination obesity shot meets goal in diabetes trial Keywords: CagriSema Outperforms Wegovy CagriSema Outperforms Wegovy

H ealth authorities have intensified monitoring efforts following the laboratory confirmation of two Nipah virus (NiV)  cases among healthcare workers in West Bengal. The patients, a male and a female nurse aged between 20 and 30, developed symptoms in late December 2025. As of late January, one patient remains on mechanical ventilation while the other has shown clinical improvement. In response, Indian authorities have tested over 190 contacts, all of whom have returned negative results. Nipah is a rare but severe zoonotic disease  primarily hosted by fruit bats, also known as flying foxes. The virus can jump to humans through direct contact with infected animals, consumption of food contaminated with bat saliva or urine (such as raw date palm sap), or through close contact with the bodily fluids of an infected person. The virus is particularly concerning due to its high case fatality rate, which ranges from 40% to 75% . Survivors may also face long-term health challenges, including persistent convulsions and neurological changes. Initial symptoms typically appear 4 to 14 days after exposure and often resemble other respiratory illnesses, featuring fever, headache, cough, and sore throat. This can rapidly progress to acute encephalitis  (brain inflammation), causing disorientation, seizures, and a coma within 24 to 48 hours. Because early symptoms are non-specific, timely diagnosis is often a significant challenge for health systems. While the World Health Organization (WHO) currently assesses the global and regional risk as low, neighboring countries like Thailand and Malaysia  have implemented health screenings at airports for travelers arriving from West Bengal. Experts emphasize that while the virus is deadly, it does not currently show signs of spreading easily between humans on a global scale. There are currently no licensed vaccines or specific treatments  for Nipah virus. Medical management relies on supportive care, though research into monoclonal antibodies and a vaccine developed by Oxford University is currently underway. Public health officials urge the public to avoid areas where bats roost, wash and peel fruits thoroughly, and avoid consuming raw date palm juice to reduce the risk of transmission. 🔖 Sources   Nipah virus: What to know after cases emerge in India   Nipah virus infection - India Everything to know about Nipah virus amid cases being detected in India Keywords: Nipah Virus Nipah Virus

P fizer Inc. reported fourth-quarter 2025 financial results on Tuesday that surpassed Wall Street’s expectations for both revenue and earnings, even as the company continues to navigate a sharp decline in its COVID-19 franchise. The pharmaceutical giant posted revenue of $17.56 billion  for the quarter, beating the $16.95 billion anticipated by analysts. Adjusted earnings per share reached 66 cents , ahead of the 57 cents predicted. Despite these beats, the company recorded a GAAP net loss of $1.65 billion , a downturn from the $410 million profit reported in the same period last year, primarily due to restructuring charges and significant intangible asset impairment costs. The decline in pandemic-era demand remains a headwind, with Comirnaty  vaccine revenues falling 35% and the antiviral Paxlovid  dropping 70%. However, Pfizer’s non-COVID portfolio showed resilience, growing 9% operationally  in the fourth quarter. Key growth drivers included the RSV vaccine Abrysvo , which saw a 136% operational increase, and the Vyndaqel  family of heart treatments. Central to Pfizer’s future growth is its high-stakes entry into the weight-loss market. The company recently completed its $10 billion acquisition of Metsera  and on Tuesday released positive Phase 2b data for an ultra-long-acting obesity injection. The study met its primary endpoint, showing significant weight loss that continued even as patients switched to once-monthly dosing . Looking toward 2026, Pfizer reaffirmed its outlook of $59.5 billion to $62.5 billion  in revenue. This guidance incorporates anticipated impacts from "price compression" linked to a landmark drug pricing deal with the Trump administration. Under this agreement, Pfizer will provide deeper discounts to Medicaid in exchange for a three-year exemption from tariffs . As the company works to cut $7.7 billion in costs  by 2027, leadership remains focused on its late-stage pipeline, planning to start approximately 20 key pivotal studies  in 2026 to offset upcoming losses of exclusivity on older blockbuster drugs.k rather than a threat to the company’s long-term cash flow from its GLP-1 portfolio. 🔖 Sources   Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance   Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand Keywords: Pfizer Financial Results Pfizer Financial Results

Image credit: The Things. Fair use. S eason 11 of Chicago Med  has pushed the boundaries of emergency medicine, featuring high-stakes structural collapses, rare congenital anomalies, and complex ethical dilemmas regarding organ donation and psychiatric care. From the discovery of "superfetation" to the management of familial prion disease, the ED staff at Gaffney Chicago Medical Center faced a relentless series of physiological and psychological challenges. Below is a comprehensive, episode-by-episode breakdown of the medical diagnoses, treatments, and clinical outcomes presented throughout the first half of the season. Content ⁉️ 1️⃣ Episode 1 2️⃣ Episode 2 3️⃣ Episode 3 4️⃣ Episode 4 5️⃣ Episode 5 6️⃣ Episode 6 7️⃣ Episode 7 8️⃣ Episode 8 9️⃣ Episode 9 🔟 Episode 10 1️⃣1️⃣ Episode 11 🔖 Key Takeaways Episode 1 Traumatic Impalement, Splenic Rupture, and Aortic Hematoma S hay and Sierra. Following a structural collapse at a rave, two sisters arrived at the ED physically joined by a traumatic impalement; Sierra’s fractured forearm bone had punctured Shay’s abdomen. A FAST scan revealed free fluid in Shay's abdomen, indicating a splenic rupture. To save them, surgeons performed a complex separation involving the amputation of Sierra’s non-viable arm and a splenectomy for Shay. The case was further complicated when Shay developed a massive aortic hematoma  and entered V-fib. She was resuscitated after 18 minutes of cardiac massage. Familial Prion Disease Dr. Lenox. A major medical storyline was introduced involving Dr. Lenox, who tested positive for familial prion disease , a terminal condition that killed her mother. While currently asymptomatic, the disease is characterized by an unpredictable progression that remains fatal within a year of symptom onset. With no cure available, treatment is currently limited to psychological management of grief and denial. Other Medical Diagnoses and Conditions Discussed Full-Thickness Burns (90%):  Required immediate intubation and chest escharotomy for respiratory distress. Deep Extremity Burns:  Necessitated early surgical debridement to prevent necrosis. Traumatic Forearm Fracture:  Involved vascular compromise requiring amputation. Traumatic Brain Injury:  Resulting from structural collapse debris. Crush Injury:  Characterized by multiple fractures and soft tissue damage. MDMA Intoxication:  Stimulant ingestion causing distorted pain perception. Acute Renal Failure:  Secondary complication of severe burn trauma. Delayed Intra-abdominal Hemorrhage:  Manifested hours after initial blunt force trauma. Episode 2 Soft-Tissue Infection Secondary to Leg-Lengthening Surgery M iles Weller. A patient presenting with fever and leg pain was found to have hidden a leg-lengthening surgery  from his fiancée. The titanium rods and gear systems used in the procedure created crevices that harbored a severe soft-tissue infection on both tibias. To prevent sepsis while preserving bone growth, surgeons replaced the complex hardware with standard intramedullary (IM) nails. Bowel Obstruction and Cocaine Toxicity Jasper. A "drug mule" presented with severe abdominal pain caused by body packing . A CT scan revealed 59 bags of cocaine, with 41 causing an obstruction at the ileocecal valve. When a packet ruptured, causing tachycardia and rising temperature, doctors performed an emergency laparotomy to remove the drugs. H. Pylori Infection and Gastric Cancer May and Jeremy. A pregnant woman and her partner presented with gastrointestinal distress. While the woman was treated for a standard H. pylori  infection, her partner’s symptoms were caused by gastric cancer  triggered by the bacteria. Diagnostic imaging revealed ascites, leading to a transition from antibiotic treatment to oncology care. Other Medical Diagnoses and Conditions Discussed Pregnancy:  Monitored via prenatal labs and ultrasound. Psychological Denial:  Defense mechanism against mortality. Morning Sickness:  Differential diagnosis for GI distress. Sympathy Indigestion (Couvade Syndrome):  Partner experiencing physical pregnancy symptoms. Gallstones:  Ruled out via ultrasound. Ascites:  Fluid accumulation indicating advanced disease. Gunshot Wound:  Trauma requiring immediate stabilization. Episode 3 Horseshoe Kidney and Traumatic Renal Failure O wen. A gunshot victim was discovered to have a horseshoe kidney , a congenital malformation where the kidneys are fused. With the right side obliterated and the left side non-functional due to perfusion issues, the patient required dialysis. He eventually received a successful transplant from his pregnant mother. Dissociative Fugue State and Trench Foot Lieutenant Daniel Hazouri. A patient found in the river with amnesia and trench foot  was diagnosed with a dissociative fugue state . It was estimated he walked 1,000 miles to escape a traumatic memory. Treatment involved EMDR therapy utilizing the sound of his own diastolic heart murmur to trigger memory reconsolidation. Other Medical Diagnoses and Conditions Discussed Body Packing:  Ingested drug balloons causing vomiting. Scalp Laceration/TBI:  GCS score of 3 following a crash. Brain Death:  Irreversible loss of brain stem reflexes. Diastolic Heart Murmur:  Abnormal heart sound disqualifying for aviation. Amnesia:  Memory loss with normal CT results. Malignancy:  Disqualifying factor for organ donation. Preeclampsia:  Hypertension risk during surgery. Fetal Decelerations:  Heart rate drop due to maternal positioning. Episode 4 Harm OCD L ionel Blake. A patient intentionally amputated his hand due to Harm OCD , believing it would prevent him from hurting others. Doctors used fMRI technology to show the patient his caudate nucleus was malfunctioning—processing thoughts with fear rather than pleasure—to convince him to accept reattachment surgery. Immune Deficiency Disorder and Sepsis Cora Cooper. A "bubble kid" with severe immune deficiency developed sepsis . Treatment required a stem cell transplant. A DNA test revealed an IVF embryo mix-up, leading to the discovery of her biological mother, who served as the donor. Lacerated Spleen (Traumatic Internal Hemorrhage) Faye Carter. A domestic violence victim presented with a lacerated spleen  initially attributed to a fall. The blunt trauma caused a slow hemorrhage, which was treated via splenic artery embolization. Other Medical Diagnoses and Conditions Discussed Bipolar Disorder:  Target for fMRI diagnostic research. Depression:  Potential for neuroimaging diagnosis. Schizophrenia:  Complex disorder targeted for machine-led diagnosis. Body Integrity Identity Disorder:  Desire for amputation of healthy limbs. Superficial Partial Thickness Burns:  Treated with Silvadene. Methamphetamine Addiction:  Substance use disorder affecting behavior. Episode 5 Prosopometamorphopsia (PMO) L ucas Early. A foster child claimed doctors were "monsters" due to prosopometamorphopsia  ("Demon Face Syndrome"), a visual perception disorder where faces appear distorted in real life but normal in 2D images. The condition was triggered by pediatric migraines caused by stress and sleep deprivation. Treatment involved green-tinted glasses. Sepsis secondary to Endometritis Jenny Roselle. A student presented with sepsis and an enlarged uterus. It was discovered she had secretly delivered a stillborn baby, leading to endometritis  and retained placenta. She required emergency surgery and IV Zosyn. Ventricular Fibrillation (V-fib) Mr. Crowley. An elderly patient suffered cardiac arrest in the treatment room. He was successfully resuscitated from V-fib  using a defibrillator, epinephrine, and amiodarone. Other Medical Diagnoses and Conditions Discussed Increased Nuchal Translucency:  Ultrasound marker for genetic abnormalities. Early-Onset Schizophrenia:  Ruled out differential for agitation. Myocardial Infarction:  Cause of death in ED. Cataracts:  Lens clouding in elderly patient. Pelvic Inflammatory Disease:  Differential for uterine symptoms. Miscarriage:  Spontaneous pregnancy loss. Pediatric Migraine:  Stress-induced headaches. Stillbirth:  In utero fetal death. Dementia:  "Rage phase" behavioral changes. Episode 6 Arsenic Poisoning and Pulmonary Embolism J abo. A patient with severe anemia and recurrent health issues was diagnosed with arsenic poisoning  from contaminated well water. The toxicity contributed to an acute pulmonary embolism . Treatment included heparin, clot ablation, and DMSA chelating agents. Intracranial Cyst Lexi Caplan. A child suffering anaphylaxis from hornet stings underwent a CT scan that incidentally revealed a life-threatening intracranial cyst . Immediate surgery was performed to remove the lesion. Subdural Hematoma (Alzheimer’s) Bert. A patient with advanced Alzheimer's presented with a subdural hematoma . Despite the condition being reversible, the medical team adhered to his advanced directive (DNR) and provided palliative care only. Other Medical Diagnoses and Conditions Discussed Foreign Body in Eye:  Plastic lodged in ocular area. Asystole:  Cardiac arrest from anaphylaxis. Radial Artery Laceration:  Vascular injury from fall. Amputation Complications:  Issues with prosthetic fit. Severe Anemia:  Hemoglobin level of 5.8. Hepatitis:  Screened via hepatic panel. Lung Cancer:  Historical condition linked to arsenic. Episode 7 Gastric Adenocarcinoma and Cytoreduction with HIPEC J eremy Lockhart. A patient with terminal gastric cancer opted for cytoreduction with HIPEC  (heated chemotherapy). The high-risk surgery to remove the tumor and circulate heated drugs was complicated by a power failure during the procedure. Vitamin A Toxicity Angelica Larson. A gymnast suffered dizziness and a broken ankle due to vitamin A toxicity . The cause was traced to excessive use of topical products (glitter, gels) containing high doses of retinol. Treatment involved cessation of the products. Other Medical Diagnoses and Conditions Discussed ICD Malfunction:  Electrical injury causing inappropriate shocks. Narcolepsy:  Management during pregnancy. Pregnancy-Related Insomnia:  Sleep disturbance. Acute Alcohol Intoxication:  BAC of 0.275. Soft Tissue Trauma:  Defensive wounds from violence. Traumatic Brain Injury:  Concussion protocol utilized. Domestic Violence Trauma:  Systemic signs of abuse. Episode 8 Invasive Abdominal Tumor J eremy Lockhart. Continuing from the previous episode, surgeons manually controlled a massive hemorrhage from the splenic artery during a power outage. The patient survived the surgery and awoke with full cognitive function despite risks of stroke. Traumatic Hemothorax Faye Carter. A domestic violence victim developed a hemothorax  after a fall re-injured her ribs. Doctors performed a makeshift chest tube insertion using a knife and bike pump hose in a non-sterile environment to stabilize her lung. Dilated Cardiomyopathy and Beta-Blocker Toxicity Linda Myers. A transplant candidate with dilated cardiomyopathy  overdosed on beta-blockers. Although stabilized, she was denied a donor heart due to the active suicide attempt and history of depression. Other Medical Diagnoses and Conditions Discussed Insomnia:  Pregnancy symptom. Alcohol Intoxication:  Severe impairment. Memory Consolidation:  Leakage during storage transfer. Hypothermia/Acidosis:  Hemorrhage complications. Cerebrovascular Accident:  Ruled out post-op. Parasomnia:  Anxiety-induced nightmares. Cocaine-Induced Cardiac Damage:  Historical factor. Clinical Depression:  Treated with SSRIs. Sepsis:  Risk of non-sterile intervention. Panic Attack:  Burnout symptom. Epistaxis:  Stress-induced nosebleed. Episode 9 Hypopituitarism (Misdiagnosed as Depression) S ebastian Hendricks. A patient treated for years for resistant depression was found to have a damaged pituitary gland  via fMRI and hormone testing. The injury, caused by sports trauma, resulted in low testosterone and symptoms mimicking depression. Treatment involved hormone replacement and removal of a deep brain stimulation device. Other Medical Diagnoses and Conditions Discussed Panic Attacks/Epistaxis:  Stress responses. Hypertension:  Elevated blood pressure. Improper Medication Metabolism:  Toxic drug accumulation. Humerus Fracture:  Trauma from crash. Active Labor:  Imminent delivery. Tibia Fracture:  Lower leg break. Neurogenic Shock:  Spinal cord injury complication. Fetal Decelerations:  Distress during labor. C5 Fracture Dislocation:  Cord compression. Parkinson’s Disease:  DBS indication. Tetraplegia:  Paralysis from cervical injury. Substance Use Disorder:  Addiction recovery. Episode 10 Superfetation and CPAM O livia. A surrogate mother was diagnosed with superfetation  (becoming pregnant while already pregnant). The younger fetus had a Congenital Pulmonary Airway Malformation (CPAM)  causing heart failure. An attempted shunt procedure failed, leading to the loss of the younger fetus to save the older one. Ultra-Rapid Codeine Metabolism Kristen Thompson. A college athlete overdosed on therapeutic cough syrup due to being an ultra-rapid metabolizer . Her body converted codeine to morphine at a dangerous rate. She was treated with Narcan. Avascular Necrosis (AVN) Ruth Williams. A dementia patient with a hip fracture was found to have avascular necrosis . A hip replacement was mandated by the court to prevent bedridden complications, despite family objections. Other Medical Diagnoses and Conditions Discussed ACL Tear:  Knee ligament rupture. Rectal Foreign Body:  Required extraction. Bronchitis:  Treated with codeine. Twin-to-Twin Transfusion Syndrome:  Differential for size disparity. Selective Fetal Growth Restriction:  Differential diagnosis. Episode 11 Arteriovenous Malformation (AVM) S uzie Mankiewicz. A patient presenting with blurry vision and seizures was diagnosed with a grade 4 Arteriovenous Malformation (AVM)  deep in the brain. She opted for high-risk resection surgery but did not survive. Amniotic Bands Lyra. An ultrasound revealed amniotic bands  constricting the umbilical cord of a pregnant breast cancer survivor. Fetal surgery was successfully performed to release the constriction and restore nutrient flow. Progressive Cervical Myelopathy Alex Tompkins. A bull rider treated for a chest wound was incidentally diagnosed with cervical myelopathy  (spinal cord compression). He refused spinal fusion surgery to continue his career, accepting the risk of paralysis. Other Medical Diagnoses and Conditions Discussed Deep Traumatic Wound:  Required surgical exploration. Cataracts:  Ruled out for vision issues. Open Pneumothorax:  Sucking chest wound. ER-Positive Breast Cancer:  Hormonal sensitivity. Pulmonary Laceration:  Lung tear. Infected Piercing:  Localized infection. Serotonin Syndrome:  Medication complication. Tonic-Clonic Seizure:  Neurological event. Tension Pneumothorax:  Air pressure emergency. 🔖 Key Takeaways 🗝️ Trauma Innovation:  The season highlighted extreme field medicine, from separating conjoined trauma victims to utilizing makeshift equipment (bike pumps and tequila) for chest tubes. 🗝️ Genetic & Congenital Rarities:  The show explored medical anomalies such as superfetation (double pregnancy), horseshoe kidneys, and ultra-rapid drug metabolism. 🗝️ Diagnostic Technology:  Advanced imaging, specifically fMRI, played a crucial role in re-diagnosing psychiatric conditions as physiological issues (e.g., Harm OCD and pituitary damage). 🗝️ Ethical Dilemmas:  The episodes frequently addressed complex ethics, including overriding DNRs, organ donation from pregnant mothers, and court-mandated surgeries for dementia patients. Keywords: Medical Diagnoses Chicago Med Season 11 Medical Diagnoses Chicago Med Season 11

P harmaceutical giant Novo Nordisk  is facing a class-action lawsuit for allegedly orchestrating a multi-year anticompetitive strategy to protect its billion-dollar diabetes franchise. The complaint, filed by South Carolina-based wholesaler Smith Drug Company , claims Novo Nordisk unlawfully delayed generic versions of its drug Victoza  to preserve profits and transition the market to its newer blockbuster, Ozempic . At the heart of the lawsuit is a 2019 settlement between Novo Nordisk and Teva Pharmaceutical . Plaintiffs allege this agreement included an "unlawful reverse payment" that prevented Teva from launching a cheaper generic version of Victoza until June 2024. Without this deal, experts argue a generic could have hit the market as early as 2023 , following the expiration of Novo’s primary patents. Key details of the alleged scheme include: 16-Month Delay : The lawsuit claims generic competition was pushed back by nearly a year and a half. Monopoly Pricing : By blocking generics, Novo and Teva were allegedly able to charge supracompetitive prices . Strategic Pivot : Plaintiffs argue the delay allowed Novo to shift prescriptions from Victoza to Ozempic  before generic alternatives could drive down prices. Victoza was a first-generation blockbuster, generating over $5 billion  in U.S. sales in 2018 alone. The lawsuit now seeks to recover hundreds of millions of dollars in overcharges on behalf of purchasers who were forced to pay higher prices for Victoza, its generic, and Ozempic. Beyond the courtroom, the U.S. Federal Trade Commission (FTC)  and the Department of Justice (DOJ)  are reviewing the 2019 settlement. A regulatory finding of anticompetitive behavior could force Novo to unwind the deal or face significant penalties. Despite the legal "noise," institutional investors appear to remain bullish  on Novo Nordisk. Data shows net inflows of $8.44 billion  over the past year, suggesting that the "smart money" views the lawsuit as a manageable risk rather than a threat to the company’s long-term cash flow from its GLP-1 portfolio. 🔖 Sources   Novo Nordisk's Victoza Lawsuit: What the Smart Money Is Watching   Novo Nordisk sued for allegedly monopolizing diabetes drug Victoza Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic Keywords: Novo Nordisk Sued Novo Nordisk Sued